Skip to content

Exelixis EXEL Common stock, shares authorized (in shares)

Common stock, shares authorized (in shares) at other companies

Summit Therapeutics logo
Summit TherapeuticsSMMT
Incyte logo
IncyteINCY
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
BridgeBio Pharma logo
BridgeBio PharmaBBIO
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Revenue$610.8M+10.0%
Gross profit$590.9M+10.2%
Operating income$251.3M+34.5%
Net income$210.5M+31.9%
EPS (diluted)$0.79+43.6%

Balance sheet

See full
Cash & equivalents$226.2M+23.1%
Total debt$169.5M-9.4%
Total equity$1.9B-9.2%
Total assets$2.6B-8.6%

Cash flow

See full
Operating cash flow$251.8M+19.1%
CapEx$1.5M-48.9%
Free cash flow$250.3M+20.1%

Valuation

See full
Market cap$13.05B+10.1%
Enterprise value$12.99B+9.5%
P/E15.7×-2.8×
P/S5.5×+0.3×

Profitability

See full
Gross margin96.4%-0.3pp
Operating margin39.4%+6.3pp
Net margin35.1%+7.1pp
FCF margin38.6%+2.9pp

Returns & leverage

See full
Return on equity41%+10.8pp
Debt / equity0.1×0.0×
Current ratio3.3×-0.2×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exelixis's common stock, shares authorized (in shares).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exelixis's common stock, shares authorized (in shares)?
Exelixis (EXEL) reported common stock, shares authorized (in shares) of $400M in Q1 2026.
How has Exelixis's common stock, shares authorized (in shares) changed year-over-year?
Exelixis's common stock, shares authorized (in shares) decreased by 0.0% year-over-year, from $400M to $400M.
What is the long-term trend for Exelixis's common stock, shares authorized (in shares)?
Over 5 years (2020 to 2025), Exelixis's common stock, shares authorized (in shares) has grown at a 0.0% compound annual growth rate (CAGR), from $400M to $400M.